Search Results - "Taraba, Jodi L."

Risk of relapse in patients receiving azithromycin after allogeneic HSCT by Kutzke, Jade L., Merten, Julianna A., Taraba, Jodi L., Mara, Kristin C., Shah, Mithun V., Hashmi, Shahrukh K., Patnaik, Mrinal M., Litzow, Mark R., Hogan, William J., Alkhateeb, Hassan B.

“…Following publication of the ALLOZITHRO trial, the FDA released a safety announcement warning that azithromycin should not be given long-term to prevent BOS in…”
Get full text

Hepatopulmonary syndrome associated with long-term use of ado-trastuzumab emtansine (T-DM1) for treatment of HER2-positive metastatic breast cancer - a case report and series by O’Sullivan, Ciara C., Higgins, Alexandra S., Alkurashi, Adham K., Ahluwalia, Vaibhav, Taraba, Jodi L., McKie, Paul M., Kamath, Patrick S., Iyer, Vivek N., Haddad, Tufia C.

“…Background The advent of antibody-drug conjugates (ADCs) represents a landmark advance in cancer therapy, permitting targeted delivery of a potent cytotoxic…”
Get full text

Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial by Haddad, Tufia C, Suman, Vera J, Giridhar, Karthik V, Sideras, Kostandinos, Northfelt, Donald W, Ernst, Brenda J, O'Sullivan, Ciara C, Singh, Ravinder J, Desta, Zeruesenay, Peethambaram, Prema P, Hobday, Timothy J, Chumsri, Saranya, Leon-Ferre, Roberto A, Ruddy, Kathryn J, Yadav, Siddhartha, Taraba, Jodi L, Goodnature, Barbara, Goetz, Matthew P, Wang, Liewei, Ingle, James N

“…We previously reported that postmenopausal women with estrogen receptor-α-positive breast cancer receiving adjuvant anastrozole 1 mg/day (ANA1) with estrone…”
Get full text

Development of oral oncolytic nonadherence estimator (ORACLE): A pretreatment nonadherence risk assessment for oral oncolytics by Signorelli, Jessie, Tran, Thuy, Sirek, Marie E, Díaz-Rohena, Yarelis, Taraba, Jodi L, Muluneh, Benyam, Basu, Nayanika, Lilly, Jennifer, Darling, Julianne

“…Introduction To date, there is no adherence estimator to identify risk of nonadherence prior to initiating oral oncolytics. Methods A workgroup was assembled…”
Get full text

Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer by Rangel, Leticia B. A., Taraba, Jodi L., Frei, Christopher R., Smith, Lon, Rodriguez, Gladys, Kuhn, John G.

“…Ethnic differences in patient genetics and breast cancer (BC) biology contribute to ethnic disparities in cancer presentation and patient outcome. We…”
Get full text

Abstract PS7-49: Assessment of patient out-of-pocket cost for palbociclib therapy in advanced breast cancer by Golbach, Allison P, Smith, Matthew D, Taraba, Jodi L, Giridhar, Karthik V

“…Abstract Assessment of patient out-of-pocket cost for palbociclib therapy in advanced breast cancerBackground:Palbociclib has demonstrated improved outcomes in…”
Get full text

Building a robust pharmacy research program: Reflections from a large healthcare system not affiliated with a college of pharmacy by Herges, Joseph R., Wieruszewski, Erin D., Barreto, Jason N., Taraba, Jodi L., Barreto, Erin F., Oyen, Lance J., Nei, Andrea M., Wieruszewski, Patrick M., Thurber, Kristina M., Schramm, Garrett E., Formea, Christine M., Rudis, Maria I.

“…Professional standards for academic health care system pharmacy departments and clinical pharmacists advocate for research and scholarly activities. Developing…”
Get full text

Relapse Rates in Patients Receiving Azithromycin for the Treatment of Bronchiolitis Obliterans after Allogeneic Hematopoietic Stem Cell Transplant by Kutzke, Jade L., Taraba, Jodi L, Merten, Julianna A, Shah, Mithun V., Hashmi, Shahrukh K., Patnaik, Mrinal M., Litzow, Mark R., Hogan, William J., Alkhateeb, Hassan B.

“…The FDA issued a warning on the increased risk of hematologic relapse based on the ALLOZITHRO trial, recommending azithromycin not be used long-term in…”
Get full text